TG Therapeutics Inc annual free cash flow for fiscal TTM was $18 million, compared with -$25 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $18M | ($25M) | ($41M) | ($31M) | ($176M) | ($296M) | ($215M) | ($133M) | ($129M) | ($94M) | ($62M) | ($45M) | ($35M) | ($11M) | ($5M) | $0M | ($2M) | ($1M) | ($4M) | ($10M) | ($8M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $39M | ($18M) | $20M | ($23M) | $7M | ($29M) | ($26M) | ($12M) | $6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More TGTX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All TGTX financial statements → Interactive TGTX charts →
About TickerBase · Data methodology & sources · Privacy · Terms